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SCIENCE FROM THE SOURCE
DR. ALISA PIEKNY Q&A 
by Shama Bhatia
HOW DID YOU GET INTERESTED IN CELL BIOLOGY?
In undergrad, it was one of my favourite courses. It was 
appealing for many reasons—although the pathways 
involved in signaling are quite complex, each pathway is 
quite logical in how it senses a signal and translates that 
signal into a response. As a graduate student, I liked how 
cell biological studies rely on combinations of in vitro and in 
vivo techniques. I particularly enjoy the use of microscopy to 
monitor physiological changes.
WHAT IS YOUR EDUCATIONAL BACKGROUND AND 
HOW HAS IT HELPED YOU GET TO YOUR CURRENT 
POSITION?
BSc Honors, Biology – Queen’s University; MSc Molecular 
Genetics – University of Calgary; PhD Biochemistry and 
Molecular Biology – University of Calgary; post-doc studying 
cell division with Dr. Glotzer, first at the Institute of Molecular 
Pathology in Vienna, Austria, then at the University of Chicago.
Staying in biology-related disciplines has helped me to obtain 
well-rounded training that included learning about organisms 
and their physiology at the genetic, molecular, cellular and biochemical levels. During graduate school, I started 
studying cytoskeletal dynamics more specifically, and this laid the groundwork for my current position, which 
includes studying the regulation of cytoskeletal dynamics for cell division, migration and adhesion. I published 
several strong papers as a graduate student, and this played a crucial role in laying the foundation for a career 
in academics.
WHAT DREW YOU TO YOUR FIELD?
Back when I was a graduate student, a pathway that specifically regulates smooth muscle contraction (e.g. gut 
and blood vessels) had recently been uncovered. This same pathway was found to work in non-muscle cells in 
vitro, where it was shown to regulate how cells moved or changed shape. The idea that there was much to be 
learned about how this pathway worked in non-muscle cells in vivo to regulate processes that were necessary 
for cell division or tissue morphogenesis was appealing.
WHAT IS A TYPICAL DAY IN YOUR LIFE AS A SCIENTIST?
I spend ~60% of my time writing, ~30% teaching (including time spent with my graduate and undergraduate 
students), and the rest on administrative duties. As someone entering the mid-stage of their career, there is a 
constant flow of manuscripts that we are working on for publications, abstracts for presentations at conferences, 
theses that students are writing for their defense, and grants, grants and more grants.
WHAT ARE YOU CURRENTLY WORKING ON IN THE LAB?
The lab has three main projects: 1. Studies of cytoskeletal regulation for cell division, using mammalian cells 
and C. elegans as model organisms. 2. Studies of cytoskeletal regulation for cell migration and shape changes 
during tissue morphogenesis using C. elegans as a model organism, and 3. Studies of the mechanism of action 
of a novel anti-cancer drug (in collaboration with several chemists).
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WHAT SORT OF BACKGROUND RESEARCH 
HAS LED TO YOUR CURRENT WORK?
 As mentioned above, as a graduate student I became 
interested in studying the regulation of cytoskeletal 
dynamics for cell shape change during C. elegans 
tissue morphogenesis. As a postdoc, I expanded on 
this knowledge by also studying this in cytokinesis in 
human cells, and work in my own lab has expanded on 
this to include studies of cell migration and adhesion.
Also, as a grad student, I learned the power of using 
model organisms to study signaling in vivo. I feel 
that genetics is superior to using ‘drugs’ on cells 
and tissues in vitro, especially those that have off-
target effects. The molecular lesion in a gene can be 
can be determined (e.g. dominant or recessive), 
and the phenotype of this lesion can be analyzed at 
the tissue, cellular or subcellular level. In addition, 
I learned how to perform different types of light 
microscopy and how to use these methods to quantify 
phenotypic changes. Advances in microscopy-based 
techniques permit studies of cells within the context of 
their native environments, which has opened the door 
to doing cell biological studies in vivo.
WHAT HAS BEEN YOUR M O S T 
INTERESTING/IMPORTANT 
SCIENTIFIC FINDING?
When I was a postdoc, I worked with a grad student 
to uncover the molecular mechanism by which the 
mitotic spindle spatially controls the division plane for 
cytokinesis (occurs at the end of mitosis to cleave the 
cell) in human cells. In particular, we showed that a 
complex forms between a protein at the central spindle 
and the activator of RhoA, which is a key regulator 
visualize the localization of RhoA during cytokinesis in 
live human cells. This work is included and referenced 
in several cell biology textbooks and laid the foundation 
for studies published in journals such as Nature, Cell 
and Developmental Cell, showing the conservation 
of this mechanism in other metazoans, and studying 
additional regulation of the complex.
WHAT HAS BEEN YOUR BIGGEST RESEARCH 
CHALLENGE?
The biggest challenge I have faced in general has 
been to stay funded. I, like most of my colleagues, 
spend most of my time writing grants, most of which 
are not successful—this is not a good use of our time. 
Imagine what we could do if we had that time freed to 
do and/or guide research being done by our students 
more closely, and for dissemination? Within the past 
decreased funding and support for basic research in 
Canada. Success rates are at or below 10% for CIHR, 
the major agency that used to support basic research in 
the health sector, and I have seen extremely talented, 
creative researchers leave academia for careers that 
offer more stability, downgrade their programs, or do 
research that is more ‘applied’ to attract funding from 
the private sector. I used to be funded by CIHR, but 
after two unsuccessful grant applications, I just gave 
up on applying to this agency altogether. It wasn’t worth 
the time I had to spend writing the grants, and while 
the feedback used to be very helpful and constructive, 
it started to denigrate to no/little feedback. What is the 
clinical researchers have the impression that basic 
research is not applicable to human health (this was 
one of the comments written at the top of my last 
application). Yet, most of the major advancements in 
human health came from basic research using model 
organisms. Not supporting this work is destroying 
Canada’s ability to be creative and be at the forefront 
of discovery.
WHAT IS THE ROLE OF TECHNOLOGY IN 
YOUR WORK?
Technology plays a crucial role in our research. We 
rely heavily on different types of light microscopy to 
image at the subcellular level. As I mentioned earlier, 
advancements in light microscopy have really opened 
the door for doing elegant, in vivo cell biological 
studies. We rely on software that can be tailored for 
our special needs to measure physiological changes 
that occur in cells. We use classic molecular and 
biochemical tools, and –omics based technology 
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(proteomics, genomics, etc.) to study pathways. We 
also are interested in transgenic techniques, such as 
CRISPR, to build tools for imaging in vivo. We are 
collaborating with scientists in other disciplines to help 
us use technologies that go beyond my expertise, 
especially in areas of biophysics, e.g. to study 
mechanobiology.
HOW IS YOUR RESEARCH APPLICABLE TO 
REAL WORLD PROBLEMS?
 Our work is applicable to cancers, which are highly 
prevalent in our aging population. What the majority 
of people don’t understand is that cancers are highly 
complex, and no two cancers are the same. Cells 
within cancers often have thousands of mutations, 
and are heterogenous—meaning that even cells 
within the same tumour may be different! At the 
core, there may be several hundred mutated genes 
that are considered to be the ‘drivers’ of the cancer, 
which are largely responsible for their development 
and progression. Thus, to improve our understanding 
of cancers, we are studying unique physiological 
changes that have occurred to try to give meaning 
to these mutations and altered signaling pathways. 
However, our work is still basic—we are building 
knowledge on the fundamental mechanisms of 
cell physiology—in particular on the regulation of 
cytoskeletal dynamics, which is crucial for events 
such as shape change, migration, and adhesion, and 
are hijacked in the development and progression of 
cancers. Also, I am collaborating with a medicinal 
chemist to develop a novel anti-cancer drug, and with 
nanochemists to optimize nanomaterials for use as 
tools for studying cell biological processes, and for the 
delivery of anti-cancer drugs in vitro and in vivo.
WHEN YOU GET FREE TIME AWAY FROM 
RESEARCH, WHAT DO YOU LIKE TO DO?
I have a four-year-old, so most of my free time is spent 
with her. We like to spend a lot of time outdoors—
walking, running and swimming. I also play soccer. 
I played on recreational teams for many years, and 
more recently have started doing training sessions. 
We also like to travel. My husband and daughter are 
also Irish and most of his family lives in Ireland or are 
abroad, so we go to visit them. We also lived in Austria 
for a few years and like to go back to continental 
Europe now and then. Like many other scientists, our 
destinations are largely determined by conferences. It 
is often a good way to incorporate an interesting family 
vacation (either before or after the meeting). Last year 
I had a conference in Slovenia, so we went to Austria 
as a family first, then I went on to the meeting.
WHAT EXCITES YOU ABOUT YOUR WORK?
Every day brings something different, with the potential 
for a new, exciting discovery. I often feel that we are 
on the cusp of something exciting, as we dig deeper 
into our scientific questions and try new experiments. 
However, it is rare to have that one experiment 
that offers a eureka moment—acquiring data takes 
time, and needs to be rigorously re-tested with the 
appropriate controls to be sure that what you have 
observed is not due to artifact. The big picture and 
impact of the data often emerges as you do the ‘next’ 
experiment to continue to test your hypothesis. That 
being said, I still get excited when observing a new 
phenotype, or a result that I know is taking us into a 
new direction with our research. I also enjoy interacting 
with my students and colleagues, on a daily basis or 
at conferences. Sharing new ideas and receiving new 
insight to your work is always refreshing.
WHAT ASPECTS OF YOUR WORK DO YOU 
LIKE THE LEAST?
Did I mention grant writing? Actually, I don’t mind 
writing grants, but I mind writing 5-10 grants a year 
(often more if you count internal grants), because it 
takes time from current research and students that 
need input, and from dissemination. I also do not 
like some of the administrative work that we have to 
do (e.g. dealing with contracts, ordering, filling out 
numerous forms, etc.). Often it is very frustrating to 
find the information you need!
WHAT IS THE ADVICE YOU WOULD LIKE 
TO GIVE TO STUDENTS INTERESTED IN 
PURSUING A CAREER IN CELL BIOLOGY?
A student who is interested in any career in science 
needs to enjoy it, and needs to be patient and diligent. 
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Figure out what you like about science, and how 
you could see yourself using this knowledge. For 
example, do you want to be an academic (research 
and teaching), or strictly a researcher (public or 
private sector), or are you interested in teaching 
(high school vs. post-secondary institution), writing 
(science writer) or business (intellectual property)? 
This may determine how you approach your training. 
To be competitive in academia or as a researcher, 
you will need to publish several high impact papers 
and carefully consider the reputation of the lab (e.g. 
to be competitive for scholarships and networking). Or 
maybe you choose a program where you can become 
a teaching assistant or do pedagogical training as part 
of your degree to get some teaching experience. Sign 
up for workshops at conferences or at your university 
that provide knowledge in more applied areas. 
Importantly, choose a lab to train in where you can 
build a positive relationship with your supervisor and/
or where there is a lot of local support. Find a mentor 
who can act as a role model, give you advice and help 
you be informed for your future decisions.
